These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 7907646

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment.
    Simberkoff MS, Hartigan PM, Hamilton JD, Day PL, Diamond GR, Dickinson GM, Drusano GL, Egorin MJ, George WL, Gordin FM, Hawkes CA, Jensen PC, Kilmas NG, Labriola AM, O'Brien WA, Oster CN, Weinhold KJ, Wray NP, Pazner SB.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb 01; 11(2):142-50. PubMed ID: 8556396
    [Abstract] [Full Text] [Related]

  • 5. Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection.
    Caiaffa WT, Graham NM, Galai N, Rizzo RT, Nelson KE, Vlahov D.
    Arch Intern Med; 1995 Oct 23; 155(19):2111-7. PubMed ID: 7575072
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Serum beta 2-microglobulin and prediction of progression to AIDS in HIV infection.
    Lifson AR, Hessol NA, Buchbinder SP, O'Malley PM, Barnhart L, Segal M, Katz MH, Holmberg SD.
    Lancet; 1992 Jun 13; 339(8807):1436-40. PubMed ID: 1351128
    [Abstract] [Full Text] [Related]

  • 9. In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus.
    Dolan MJ, Clerici M, Blatt SP, Hendrix CW, Melcher GP, Boswell RN, Freeman TM, Ward W, Hensley R, Shearer GM.
    J Infect Dis; 1995 Jul 13; 172(1):79-87. PubMed ID: 7797948
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.
    Volberding PA, Lagakos SW, Grimes JM, Stein DS, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS, Phair JP, Mitsuyasu RT.
    JAMA; 1994 Aug 10; 272(6):437-42. PubMed ID: 7913730
    [Abstract] [Full Text] [Related]

  • 12. Serum beta 2-microglobulin and prediction of progression to AIDS in HIV-infected injection drug users.
    Zabay JM, Sempere JM, Benito JM, Gonzalez B, Obregón E, Díez J, Fernández-Cruz E.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar 01; 8(3):266-72. PubMed ID: 7859138
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel FD, Bruun JN, Stingl G, Melville RL, González-Lahoz J.
    N Engl J Med; 1993 Jul 29; 329(5):297-303. PubMed ID: 8100611
    [Abstract] [Full Text] [Related]

  • 17. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
    Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng TC, Fischl MA, Collier AC, Phair JP, Hirsch MS.
    N Engl J Med; 1995 Aug 17; 333(7):401-7. PubMed ID: 7616988
    [Abstract] [Full Text] [Related]

  • 18. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
    Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS.
    N Engl J Med; 1990 Apr 05; 322(14):941-9. PubMed ID: 1969115
    [Abstract] [Full Text] [Related]

  • 19. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee.
    Lancet; 1994 Apr 09; 343(8902):871-81. PubMed ID: 7908356
    [Abstract] [Full Text] [Related]

  • 20. Logarithmic relationship of the CD4 count to survival in patients with human immunodeficiency virus infection.
    Nightingale SD, Jockusch JD, Haslund I, Cal SX, Peterson DM, Loss SD.
    Arch Intern Med; 1993 Jun 14; 153(11):1313-8. PubMed ID: 8099477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.